Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial PMC Unleashing the power of retatrutide: A possible triumph over obesity and overweight: A correspondence PMC TripleHormone-Receptor Agonist Retatrutide for Obesity A Phase 2 Trial | New England Journal of Medicine NowPatient has taken all reasonable steps to ensure that all material is factually accurate, complete, and current
Topical application is generally considered the lowest risk because very little of the ingredient reaches the bloodstream
Previous medications in this space include Semaglutide (marketed as Wegovy and Ozempic) and Tirzepatide (marketed as Mounjaro and Zepbound)

FDA approves first treatment to reduce risk of serious heart problems specifically in adults with obesity or overweight, Food & Drug Administration, 2024 Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes, New England Journal of Medicine (2023) Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis, Cardiovascular Diabetology (2019) Wegovy (semaglutide): A new weight loss drug for chronic weight management, Journal of Investigative Medicine (2022) Oral semaglutide, Clinical Diabetes (2020) Efficacy of semaglutide in a subcutaneous and an oral formulation, Frontiers in Endocrinology (2021) Wegovy Dosing Schedule, Novo Nordisk Effect of semaglutide on the pharmacokinetics of metformin, warfarin, atorvastatin, and digoxin in healthy subjects, Clinical Pharmacokinetics (2017) Metformin, MedlinePlus (2024) Common Side Effects of Wegovy, Novo Nordisk Updates about Wegovy, Novo Nordisk (2024) FAQs about Wegovy, Novo Nordisk Oral semaglutide versus empagliflozin in patients with Type 2 diabetes uncontrolled on metformin: The PIONEER 2 Trial, Diabetes Care (2019) Medically accurate: SingleCares Medical Review Board analyzes all of our content to confirm its in line with current medical advice

Were diagnosed with Mounjaro and vision loss , NAION, detached retina , or an optic nerve injury
Flanagan JL, Simmons PA, Vehige J, Willcox M, Garrett Q